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YeastAs a mammalian p-glycoprotein homolog, Pdr5p is a major ATP-binding cassette transporter for cellular
detoxiﬁcation in the yeast Saccharomyces cerevisiae. In this study, two novel loss-of-function mutations
located adjacent to the ends of the predicted transmembrane helices of Pdr5p were identiﬁed. C793F
and S1230L mutations considerably impaired the transport activity of Pdr5p without affecting the ATPase
activity and the expression level of the protein. Our results demonstrate that the size of residue 793 and
the hydrophobicity of residue 1230 are important for Pdr5p efﬂux function. It reveals that amino acid
residues located near the end of transmembrane helix play an important role in drug efﬂux of Pdr5p.
Molecular docking results further suggest that these two single mutations might have disturbed
interactions between the drugs and Pdr5p, preventing the drugs from approaching the intracellular or extra-
cellular portal and subsequently from being exported by Pdr5p.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Efﬂux of xenobiotics by ATP-binding cassette (ABC) transporters is a
majormechanismemployed by various cells to survive in toxic environ-
ment [1]. As the best-studied and most abundant ABC transporter in
Saccharomyces cerevisiae, Pdr5p mediates cellular detoxiﬁcation and
multidrug resistance (MDR) [2,3]. The predicted topological structure
of Pdr5p shows that it contains two nucleotide binding domains
(NBDs) and two transmembrane domains (TMDs)which harbor twelve
transmembrane helices (TMHs), six extracellular loops (ECLs) and four
intracellular loops (ICLs) [4,5].
Pdr5p shares similar secondary topological structure with
other homologous ABC transporters and is presumed to extrude
substrates by continuous switching between inward-facing
and outward-facing conformations, which are believed to have dif-
ferent afﬁnities towards the transported substrates [2]. Although TMDs
of ABC transporter are not conserved in length or sequence, it is well ac-
cepted that TMDs are essential for substrate recognition, binding and
translocation, and the amino acid residues within TMHs might play
the important roles [6–9].ights reserved.To clarify the mechanisms of how Pdr5p recognizes and extrudes a
wide variety of compounds out of the cells, numerous mutants had
been generated by random or site-directed mutagenesis [10–16].
Despite the effort, the structure–function mechanism of Pdr5p still
remains unclear [17–19]. A number of single-point mutations within
the TMDs had reportedly altered drug speciﬁcity or impaired drug-
efﬂux efﬁciency of Pdr5p [10–12,14,20]. Some of them were thought
to have altered how substrates gain access to or release from the
substrate-binding pocket through the portal while the others were
shown to be defective in the cross-talk between TMDs and NBDs during
the catalytic cycle of Pdr5p.
In this study, we identiﬁed two novel loss-of-function mutations
C793F and S1230L within the TMDs of Pdr5p. To investigate the poten-
tial loss-of-function mechanism, C793 and S1230 were individually
substituted with various amino acids and drug susceptibility of each
mutant was evaluated. Furthermore, we used a recent published 3D
model of Pdr5p to perform an independent docking study, shedding
more light into the structure–function relationship of Pdr5p.
2. Materials and methods
2.1. Strains, plasmids and media
The strains and plasmids used in this study are listed in Table 1.
S. cerevisiae BY4741 cells were grown in synthetic complete medium
Table 1
Strains and plasmids used in this study.
Strains or plasmids Relevant characteristics References
S. cerevisiae BY4741 MATa his3 leu2 metl5 ura3 Yeast Knock-out (YKO) deletion collection
E. coli DH5a supE44, AlacU169 (q80lacZAM15), hsdR17, recA1, endA1, gyrA96,thi-1, relA1
BY4741Apdr5::YEplac195 (DEL) MATa his3 leu2 met 15 ura3 pdr5::loxP [18]
BY4741Apdr5::YEplac195-BPDR5 (WT) MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5 [18]
BY4741Apdr5::YEplac195-BPDR5-C793M MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-C793M This study
BY4741Apdr5::YEplac195-BPDR5-C793S MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-C793S This study
BY4741Apdr5::YEplac195-BPDR5-C793F MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-C793F This study
BY4741Apdr5::YEplac195-BPDR5-C793Y MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-C793Y This study
BY4741Apdr5::YEplac195-BPDR5-S1230F MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-S1230F This study
BY4741Apdr5::YEplac195-BPDR5-S1230Y MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-S1230Y This study
BY4741Apdr5::YEplac195-BPDR5-S1230A MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-S1230A This study
BY4741Apdr5::YEplac195-BPDR5-S1230N MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-S1230N This study
BY4741Apdr5::YEplac195-BPDR5-S1230L MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-S1230L This study
BY4741Apdr5::YEplac195-BPDR5-S1230P MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-S1230P This study
BY4741Apdr5::YEplac195-BPDR5-E794K MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-E794K This study
BY4741Apdr5::YEplac195-BPDR5-E794Q MATa his3 leu2 met 15 ura3 pdr5::loxP PDR5-E794K This study
Plasmids
YEplac195 ATCC 87589
YEplac195-BPDR5 [18]
YEplac195-BPDR5-C793M This study
YEplac195-BPDR5-C793S This study
YEplac195-BPDR5-C793F This study
YEp\ac195-BPDR5-C793Y This study
YEp\ac195-BPDR5-S1230F This study
YEp\ac195-BPDR5-S1230Y This study
YEp\ac195-BPDR5-S1230A This study
YEp\ac195-BPDR5-S1230N This study
YEp\ac\95-BPDR5-S1230L This study
YEp\ac\95-BPDR5-C793FS1230L This study
YEp\ac\95-BPDR5-E794Q This study
YEp\ac\95-BPDR5-E794K This study
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host strain for all plasmid constructions and grown in LB medium
with 50 μg/ml ampicillin.
2.2. Chemicals
Cycloheximide (CYH), rhodamine 6G (R6G) and FK-506monohydrate
were dissolved in ethanol, whereas the 2,3,5-Triphenyltetrazolium
chloride (TTC) and ﬂuconazole (FLC) stock solutions were prepared
with sterile water. All reagents above were purchased from Sigma-
Aldrich.
2.3. Random and site-directed mutagenesis
PCR-targeted random mutagenesis was performed as previously
described [21] and functional impaired mutants were screened using
SD-ura agar plate containing 20 μM FLC. The detailed procedure
of random mutagenesis and mutant screening is described in
Supplementary materials.
Site-directed mutagenesis was performed using QuickChange
kit (Stratagene) and YEplac195-BPDR5 was used as the template.
The resulting mutants were conﬁrmed by DNA sequencing. The
primers used in sequencing and mutagenesis are listed in Table S1
(Supplementary materials). All the mutational YEplac195-PDR5 series
were transformed into pdr5-null mutant strain following LiAc/SS carrier
DNA/PEG method as previously described [22].
2.4. Preparation of puriﬁed membrane vesicles and immunoblotting
The plasma membrane (PM) vesicles were puriﬁed as previous-
ly described [13,16]. The concentration of membrane protein in
the vesicles was determined by micro-Bradford assay (Bio-Rad
Laboratories). Protein proﬁles (20 μg/lane) were examined by 7%sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) followed by Coomassie Blue staining. Western blotting
was carried out with a Pdr5-speciﬁc antibody yN-18 and a Pma1-
speciﬁc antibody yN-20 (Santa Cruz Biotechnology, Santa Cruz,
CA). yN-18 and yN-20 were 600- and 1000-fold diluted in Tris-
Buffered Saline Tween-20 (TBST), respectively. HRP labeled donkey
anti-goat polyclonal antibody (Beyotime Biotech, China) was
diluted 1:3000 in TBST. Proteins were visualized byECL chemilumines-
cence detection system (Beyotime Biotech, China) according to the
manufacturer's instructions.
2.5. Drug resistance assays
Fresh yeast cells of BY4741Δpdr5::YEplac195-BPDR5 (WT), BY4741
Δpdr5::YEplac195 (pdr5Δ) and BY4741Δpdr5::YEplac195-PDR5*
harboring various PDR5mutant genes were inoculated to 5 ml SD-ura
media and grown overnight at 30 °C. Then the cell suspensions were
diluted to OD600 of 0.1 with sterile SD-ura medium. 6 μl of 5-fold serial
dilutions was spotted on SD-ura agar plates containing FLC, CYH or TTC.
The plates were incubated at 30 °C for 48 h before scanning. Equal
amounts of cells (ﬁnal OD600 = 0.1) were cultured in 200 μl SD-ura
media containing FLC, CYH or TTC and the ﬁnal OD600 were measured
by spectrophotometry after incubation at 30 °C with shaking at
250 rpm for 24 h. The mean relative growth rate was determined by
OD600 ratio of the cell samples cultured in SD-ura media with/without
the drugs.
2.6. Determining the inhibitory concentration 50 (IC50) of a drug in
liquid culture
Fresh yeast cells were inoculated to 5 ml SD-uramedium and grown
overnight at 30 °C. Then the cultures were diluted to OD600 of 0.1 with
sterile SD-ura medium. 200 μl of above cultures were transferred to a
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Fig. 1.Growth of theC793F and S1230Lmutantswas inhibited by FLC. (A)The susceptibility
of the C793F and S1230L mutants to FLC was compared in spot assay. Spots were prepared
with 1:5 serial dilutions of the cell suspensions (OD600 = 0.1). The drug plates were
incubated at 30 °C for 48 h. (B) The susceptibility of the C793F and S1230L mutants
to FLC was also compared in liquid culture. OD600 was measured after 24 h incubation.
Each point is the average of three samples. (C) Schematic representation based on a
topology prediction [4] of Pdr5p, showing the positions of C793 and S1230.
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The 96-well plate was then incubated for 24 h at 30 °C with shaking
(250 rpm). The percent inhibition was determined by the ratio of
OD600 of the culture grown in the presence or absence of a drug at
various concentrations and the test was repeated for three separate
inoculations unless indicated otherwise. Data points were plotted
using GraphPad Prism 5 software and the IC50 values were determined
from the graph.
2.7. Rhodamine 6G (R6G) transport assay
Transport of R6Gwas determined as previously described [11]. Yeast
cells were grown in SC-ura media to an OD600 of 2. To measure dye ef-
ﬂux, cells were washed with 50 mM HEPES buffer (pH7) twice and
resuspended in 500 μl 50 mM HEPES buffer containing 5 μM or 50 μM
R6G, followed by a 60 min incubation at 30 °C. After a centrifugation
for 15 min at 12,000 g and 30 °C, cells were resuspended in pre-
warmed 50 mM HEPES buffer containing 2.5 mM glucose to initiate
R6G efﬂux. After incubation for 40 min at 30 °C, R6G efﬂuxwas stopped
by 5 min incubation on ice. The cells were washed with pre-cooled
50 mM HEPES buffer once and resuspended in 500 μl HEPES buffer.
Intracellular rhodamineﬂuorescencewas analyzedwith BeckmanCoulter
(Cytomics FC500MCL) using CXP software.
2.8. ATPase activity assay
Pdr5p-associated ATPase activities of the puriﬁed PM were
measured as previously described [13,16,23]. Puriﬁed PM vesicles
(0.5 μg protein per well) were incubated with 5 mM ATP in 25 μl
150 mMMOPS Buffer (pH7.5) containing 50 mM KNO3, 10 mM NaN3,
0.2 mM (NH4)2MoO4, 5 mM MgCl2 and 10 μM sodium orthovanadate
(Na2VO4) for 20 min at 30 °C. The reactions were terminated by
the addition of 175 μl ice-cold 40 mM H2SO4. The amount of released
inorganic phosphate was determined by a colorimetric assay, using
Na2HPO4 as standard [24]. The absorbance data were collected by
using a Power Wave XS microplate spectrophotometer equipped with
Gen5 software (BioTek).
2.9. Molecular docking
The structures of CYH, FLC, TTC and R6G were downloaded from
PubChem with CID 6197, 3365, 9283 and 13806, respectively. LigPrep
program in Maestro (v9.0) was used to optimize the structures of four
compounds with the default parameters. The inward-facing structure
of Pdr5p [4] based onmouse P-glycoprotein template [19]was prepared
as follows. First, hydrogen atomswere added. Then, the resultant struc-
ture was energy-minimized for 1000 steps using the OPLS_2005 force
ﬁeld [25] with all the non-hydrogen atoms constrained to their original
positions. The Glide program (v4.0) [26,27] was used to predict the
binding conformation between a compound and the inward-facing
structure of Pdr5p. First, the inward-facing structure of Pdr5p was
prepared using the protein preparation wizard in Maestro, and all the
parameters were set to default except that the minimization was for
hydrogens only. Then the two receptor grids were generated as follows:
C793 and S1230 were deﬁned as the centroid of Enclosing Box. The size
limit of the box was set to 20 Å. These two Enclosing Boxes were
deﬁned as two binding pockets around C793 and S1230. The atoms in
C793 and E794 that could participate in hydrogen bonding were picked
in the constraints section for the grid generation of the binding pocket
around C793, and the atoms in S1230 that could participate in hydrogen
bondingwere picked in the constraints section for the grid generation of
the binding pocket around S1230. Other parameters used in receptor
grid generationwere set to their defaults. Finally, each of the three com-
poundswere docked to the two binding pockets using the standard pre-
cision mode. During docking, 500,000 poses per ligand for the initial
phase of docking were kept and 40,000 poses per ligand for energyminimization were kept. The constraints for hydrogen bonds were set
to match at least once, and test constrain satisfaction was applied only
after docking. For each compound–binding pocket pair, Glide reported
20 best binding conformations in both precision modes.3. Results
3.1. Isolation of loss-of-function Pdr5p mutants
Previous studies had identiﬁed several loss-of-function mutants
conferred by single amino acid change within TMHs or NBDs of
Pdr5p [11–16]. To identify more novel mutations important for Pdr5p
function, Pdr5p variants were created by random mutagenesis.
After screening, two novel mutants (C793F and S1230L) exhibiting
FLC hypersensitivity similar to pdr5Δ cells were identiﬁed. As shown
in Fig. 1, the mutants are hypersensitive to FLC both on agar plates
and in liquid media. The S1230L mutant was more sensitive to FLC
(IC50 of ~15 μM) than the C793F mutant (IC50 of ~65 μM) correspond-
ing to a ~4 fold difference in sensitivity, whereas the WT strain and
the pdr5Δ strain had FLC IC50 of ~160.1 μM and ~4.9 μM, respectively
(Table S2).
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Fig. 2. Growth of the C793F and S1230L mutants was also inhibited by CYH and TTC.
(A) The susceptibility of the C793F and S1230L mutants to CYH and TTC was compared
in spot assay. Spots were prepared with 1:5 serial dilutions of the cell suspensions
(OD600 = 0.1). The drug plates were incubated at 30 °C for 48 h. The susceptibility
of the C793F and S1230L mutants to CYH (B) and TTC (C) was also compared in liquid
culture. OD600 was measured after 24 h incubation. Error bars represent the standard
deviations of triplicate experiments.
Fig. 3. R6G transport was impaired in the S1230L and C793F mutants. The data were
shown from the experiment in which 50 μM R6G was preloaded for 60 min into cells at
30 °C in buffer lacking glucose prior to efﬂux in HEPES buffer containing 2.5 mM glucose
for 40 min. Plots were constructed from counts of 50,000 cells per sample.
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Fig. 4. Pdr5p expression level, localization and ATPase activity were not affected by the
C793F and S1230 mutations. (A) Expression levels of mutant Pdr5 proteins. Membrane
protein was isolated as described in Materials and methods and subjected to SDS-PAGE
followed by Coomassie Blue staining (lower panel) and anti-Pdr5 western blotting
(upper panel). (B) Pdr5p-speciﬁc ATPase activities of the C793F and S1230L mutants.
The values represent at least three independent experiments carried out with three
different plasma membrane vesicle preparations of each strain.
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The Pdr5p substrates FLC, CYH, R6G and TTC [12] are different in size,
hydrophobicity, chemical composition and surface charge density
(Table S3). To investigate whether C793F and S1230L mutants cause
a global reduction in drug efﬂux, we studied the drug susceptibility of
the mutants towards CYH and TTC and their intracellular accumulation
of R6G.
As shown in Fig. 2A, bothmutants are hypersensitive to CYHand TTC
on the agar plates. Growth of cells harboring the C793F or S1230L
mutant was clearly reduced in the liquid media containing CYH
(Fig. 2B) or TTC (Fig. 2C) at the indicated concentrations. IC50s
were about 156 nM (CYH) and 535 μM (TTC) for C793F cells, and
about 124 nM (CYH) and 357 μM (TTC) for S1230L cells (Table S2).
These values were higher than those of the pdr5Δ cells, but much
lower than those of theWT cells, demonstrating markedly impaired ef-
ﬂux of CYH and TTC in these mutants. There was no evidence of Pdr5p
drug speciﬁcity change caused by C793F or S1230L mutation.
The intracellular accumulation of R6G was determined by ﬂow
cytometry analysis of dye-preloaded cells expressing Pdr5 mutants
(Fig. 3). Yeast cells expressing the C793F or S1230L mutant exhibitedan increased intracellular ﬂuorescence intensity compared with that of
WT Pdr5p, demonstrating their reduced R6G efﬂux capacity. To rule
out other possibilities leading to drug hypersensitivity of the mutants,
we then isolated PM fractions to study the expression level, subcellular
localization and Pdr5p-speciﬁc ATPase activity of the mutants. Our
results showed that the expression levels of C793F and S1230Lmutants
were nearly identical to that of wild-type Pdr5p (Fig. 4A) and no
obvious reduction of ATPase activity was observed in these mutants
(Fig. 4B). It indicates that neither C793F nor S1230L mutation affects
ATPase activity, protein localization, or expression level of Pdr5p.
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Fig. 5.Mutational analysis of Pdr5. (A) Spot assay on SD-ura agar plates containing CYH,
FLC, TTC, respectively. Liquid culture assay of drug resistance of C793 (B) and S1230
(C) mutants in SD-ura liquid medium containing CYH. Error bars represent the standard
deviations of triplicate experiments.
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suppressant FK506, a known inhibitor/substrate of Pdr5p [20], on cells
harboring S1230L or C793F mutation. As shown in Fig. S3, pdr5Δ cells
were unable to grow in the presence of 2 μg/ml FLC, whereas cells
harboring WT Pdr5, S1230L or C793F mutant exhibited no obvious
growth inhibition. Simultaneous exposure of WT cells and C793F
mutant to both FLC and FK506 totally abolished growth, demonstrating
inhibition of FLC transport by FK506. However, the S1230L mutant
exhibited a decreased FK506 inhibition, suggesting that S1230L
mutation might have disturbed FK506–Pdr5 interaction.Table 2
Drug susceptibility ranking of S. cerevisiae cells expressing the wild type and mutant
variant of Pdr5p.
Drug (conc.) Residue position Drug susceptibility
CYH (178 nM) C793 Y N F N M, S, C
FLC (49 μM) C793 Y N F N M N S, C
TTC (0.5 mM) C793 Y N F, M N S, C
CYH (178 nM) S1230 L N F N Y, A, N N S
FLC (49 μM) S1230 L N F N N N Y, A, S
TTC (0.5 mM) S1230 L N F N Y N A N N N S3.3. Residue substitution study at positions 793 and 1230
To understand how substitution of C793F or S1230L impairs Pdr5p-
mediated drug efﬂux, C793S, C793M, C793Y, S1230A, S1230Y, S1230N
and S1230F mutants were generated by site-directed mutagenesis
to compare their drug susceptibility. As shown in Fig. 5, besides
C793F and S1230L, the C793Y mutant was also hypersensitive to all
drugs tested on the agar plates (Fig. 5A) and to CHY in liquid media
(Fig. 5B). The drug resistance assays showed that the C793Y mutant
was more sensitive to the drugs tested than the C793F mutant.
As shown in Table S2, the C793Y mutant exhibited lower IC50s than
the C793F mutant in the present of the drugs. The expression level,
subcellular localization and ATPase activity of the C793Y mutant were
similar to that of wild-type Pdr5p (Fig. S1).
Table 2 shows the drug susceptibility ranking of all the Pdr5mutants
mentioned above towards the chemicals tested at a selected concentra-
tion. Generally, at position 793, substituting Cys (volume: 108.5 Å3)
with a bulky residue, Met (162. 9 Å3), Phe (189.9 Å3) or Tyr (193.6 Å3)
[28] increasingly impaired Pdr5p-mediated substrate efﬂux capacity
whereas substituting with the small Ser (89 Å3) did not show obvious
effect (Fig. 5B). Similar to Cys, Tyr is a polar residue, but the C793Y
mutant is more sensitive towards the drugs than the C793F mutant,
indicating that residue hydrophobicity is not important at position 793.
At position 1230, according to the estimated contribution of the
hydrophobic effect to the burial of amino acid residue calculated by
P. Andrew Karplus [29], residue hydrophobicity is systematically in-
creased by replacing the serine residue (1.4 kcal/mol) withmore hydro-
phobic Tyr (2.81 kcal/mol), Phe (3.46 kcal/mol) or Leu (4.1 kcal/mol),
respectively. As shown in Fig. 5C, the sensitivity of the S1230mutants to-
wards CYH indeed increased with the rise of residue hydrophobicity.
However, residue size is not important at position 1230, because
substitution of Ser (89 Å3) with Tyr (193.6 Å3) did not change the drug
resistance pattern of Pdr5p. These results indicate that size of the residue
at position 793 and hydrophobicity of the residue at position 1230 are
important for drug efﬂux.
3.4. Double mutant analysis
According to a recent published 3D model [4], TMH6 and TMH7
of Pdr5p comprise approximately amino acid residues 772–795 and
1203–1228, respectively. S1230 is located at the extracellular end of
the predicted TMH7, whereas C793 is located at the intracellular end
of the predicted TMH6 (Fig. 1C). Our mutant analysis revealed that
both the C793F and S1230L mutants conferred drug hypersensitivity
compared with WT Pdr5p, but they probably rely on different
mechanisms. To further investigate the role of the two residues, we
constructed the C793F/S1230L double mutant.
Like the C793F and S1230Lmutants, the expression level, subcellular
localization or ATPase activity of the double mutant was similar to
that of WT Pdr5p (Fig. 6A, B). As shown in Fig. 6C, the double mutant
protein exhibited a markedly decreased CYH resistance, demonstrating
that there is additive effect of the two mutations. IC50s were about
84.1 nM (CYH), 6.9 μM (FLC) and 128 μM (TTC) for C793F/S1230L cells
(Table S2). These values were similar to those of the pdr5Δ cells.
In addition, similar to WT Pdr5p, the intracellular accumulation of
R6G in the C793F/S1230L mutant showed no obvious change both at
low and high R6G concentrations (5 μM and 50 μM) in the presence
of CYH (Table 3), TTC and FLC (Table S4), indicating that the drugs tested
could not compete with R6G efﬂux in the cells expressing S1230L, C793F
or the double mutant. It revealed that neither C793 nor S1230 belongs
to the common binding sites for R6G and the drugs tested.
3.5. Docking of the drugs to Pdr5p
In order to evaluate the interactions between Pdr5p and the
four drugs, we performed docking experiments on Pdr5p. Our docking
AB
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Fig. 6. The C793F/S1230L double mutant exhibited a markedly decreased CYH resistance.
(A) Expression levels of mutant Pdr5 protein. Protein was isolated as described in
Materials and methods and subjected to SDS-PAGE followed by Coomassie Blue staining
(lower panel) and anti-Pdr5 western blotting (upper panel). (B) Pdr5p-speciﬁc
ATPase activity of the C793F/S1230L double mutant. The values represent at least three
independent experiments carried out with three different plasma membrane vesicle
preparations of each strain. (C) Liquid culture assay of CYH resistance of the double mu-
tant. Each point is the average of three samples.
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with themodeled inward-facing conformation of Pdr5pwith satisfactory
ﬁtness scores.Table 3
The intracellular R6G accumulation of Pdr5 mutants in the presence of cycloheximide.
Relative % of intracellular R6G
R6G 5 μM
CYH 0 μM CYH 0.18 μM CYH 0.53 μM CYH 0.
PDR5 11.5 17.8 14.1 14.9
pdr5▵ 76.5 67.8 56.9 65.4
C793F 29.2 26.3 26 25.6
S1230L 65.6 61.8 60.2 57.7
C793F S1230L 64.3 59.8 56.7 62.8Docking of the drugs to modeled Pdr5p showed that CYH, FLC and
R6G could be docked into the binding pocket containing C793 and
E794 in the inward-facing conformation of Pdr5p (Fig. 7B–D). Though
there is no direct interaction between the C793 and the compounds,
the E794 does form hydrogen bonds with CYH, FLC and R6G except
TTC. C793 is a medium sized residue and its mutation may interfere
with the hydrogen bond interactions between E794 and the substrates.
These hydrogen bonds are in locations that may help stabilize the
conformations of Pdr5p substrates for passing through the transport
channel efﬁciently.
According to the docking experiments, S1230 directly formed
hydrogen bonds with all the compounds except TTC (Fig. 7F–H).
Because S1230 is close to the extracellular end of the predicted
TMH7, the mutation at this residue may prevent the drugs from ap-
proaching the extracellular portal and subsequently their release
from Pdr5p by disturbing the hydrogen bond formation of the
drugs with S1230.
Our docking analysis found no hydrogen bond interaction between
TTC and the two residues above (Fig. 7E, I). In fact, TTC has three
hydrogen donors and no hydrogen acceptor, whereas the other three
compounds have at least 6 donors/acceptors (Table S3). Three benzene
rings around the central tetrazoliummake it hard for external hydrogen
acceptors to access these donors. Lacking hydrogen bonds between TTC
and Pdr5p implied an inferior ﬁtting between TTC and the Pdr5p
channel. As shown in Table S5, TTC exhibited quite strong van der
Waals interactions with the drug-binding pockets. The results indicate
the structural basis for the sensitivity of the mutants to TTC.
4. Discussion
To understand the structure–function relationship of Pdr5p,we used
PCR-targeted randommutagenesis to generate Pdr5 mutants and iden-
tiﬁed two novel single mutations that led to signiﬁcant reduction in
Pdr5p-mediated FLC resistance. The drug-susceptibility assay conﬁrmed
that both the C793F and S1230L mutants could not effectively extrude
four physically and chemically diverse drugs tested. It is noteworthy
that both mutants retained Pdr5p-speciﬁc ATPase activity. To explore
the loss-of-function mechanisms of these mutations, Cys793 and
Ser1230 were substituted with a series of amino acids different in size
or hydrophobicity. Our results demonstrate that the relatively small
size of residue 793 and the hydrophobicity of residue 1230 are impor-
tant for Pdr5p function.
Residue C793 is located adjacent to the intracellular end of the
predicted TMH6 of Pdr5p, near the predicted intracellular boundary of
the substrate-binding pocket. Although C793 is not conserved according
to sequence alignment result, high conservation of its neighboring resi-
due E794 in fungal ABC transporter gene family suggests that certain
property of the residue at position 793 may be of some functional
importance (Fig. S1). Our site-directed mutagenesis result conﬁrmed
that the E794Q and E794Kmutants exhibited markedly impaired efﬂux
of R6G, demonstrating that the negatively charged residue at position
794 is very important for Pdr5p function (Fig. S4). Interestingly,
such phenomenon had also been observed in our previous work on
the A1352M mutant [16]. Like E794, a highly conserved E1353, theR6G 50 μM
89 μM CYH 0 μM CYH 1.8 μM CYH 5.3 μM CYH 8.9 μM
17.0 15.2 15.5 15.3
81.9 90.7 91.9 90.6
53 57.2 54.5 53.3
73.1 75.9 75.1 75.5
89.3 89 88.5 89.6
Fig. 7. Substrate docking in Pdr5p. (A) Stereoscopic view of the Pdr5p model based on mouse P-glycoprotein template. The two modeled TMDs, colored powder-blue and pink,
are embedded in a membrane bilayer. Underneath the TMDs are the NBDs (NBD1 in blue, NBD2 in red). The extracellular loops sit above the TMDs (yellow). Residues C793 and S1230
are marked with red dashed line [4]. Predicted binding models of CYH (B), FLC (C), R6G (D) and TTC (E) to Pdr5p around C793. Predicted binding models of CYH (F), FLC (G), R6G (H)
and TTC (I) to Pdr5p around S1230. Hydrogen bonds are depicted with dashed lines.
938 Z. Chen et al. / Biochimica et Biophysica Acta 1838 (2014) 932–939neighboring residue of A1352, is also located at the intracellular
interface of the substrate-binding pocket. Replacement of A1352 with
bulky methionine severely disturbed the transport activity of Pdr5p.
These results reveal that the bulky residue substitution at the neighbor-
ing residues of E794 or E1353 impairs the efﬂux capability of Pdr5p
without disturbing its ATPase activity, implying that these conserved,
charged residues located at the membrane–cytosol interface of TMHs
are important for the binding/transport of efﬂux pump substrates.An increased residue size at position 793 may block Glu794 from
forming hydrogen bonds or van der Waals interactions with the drugs,
resulting in impaired efﬂux capability of Pdr5p. According to the recent
topological structure model reported, Pdr5p contains over 13 charged
residues predicted to reside at the membrane–cytosol interface
of TMHs, and most of them are highly conserved [4]. Thorough investi-
gation on these conserved, charged residues will provide more insight
into the function–structure relationship of Pdr5p.
939Z. Chen et al. / Biochimica et Biophysica Acta 1838 (2014) 932–939In contrast to C793, S1230 is proximal to the extracellular end of the
predicted TMH7. S1230 is highly conserved among fungal Pdr proteins
(Fig. S1), indicating that it may play a very important functional role
in Pdr5p-mediate drug export. It was found that substituting the polar
serine with a highly hydrophobic leucine (S1230L) indeed resulted in
severe impairment on drug efﬂux. Although four chemicals tested in
this study have different scale of hydrophobicity (determined as logP),
the S1230L mutant exhibited no obvious substrate speciﬁcity change.
Replacing Ser1230 with bulky residues had no obvious effect on the ef-
ﬂux capacity of Pdr5p, implying that S1230 is probably not located
at a critical location that may prevent substrates from passing through
the transport channel.
Furthermore, the molecular docking results suggested that these
two single mutations might have disturbed hydrogen bond formation
and van der Waals interactions of Pdr5p with the tested drugs,
preventing the drugs from approaching the intracellular or extracellular
portal, and subsequently impaired the efﬂux efﬁciency of Pdr5p.
In summary, our new observation that both the C793F and S1230L
mutants considerably impaired the transport activity of Pdr5p without
affecting the ATPase activity, localization and the expression level
of the protein paves a way for future investigations on the role of
TMH-interface residues in substrate transport.
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